title: Immunosuppressive therapy in adults with aplastic anaemia: single-institution experience from India.
abstract: OBJECTIVE
  To determine overall survival and factors predicting survival after immunosuppressive therapy in patients with acquired aplastic anaemia.
  
  
  METHODS
  Retrospective.
  
  
  METHODS
  Tertiary care hospital.
  
  
  METHODS
  120 adults diagnosed as having acquired aplastic anaemia between 1 January 1996 and 31 December 2009.
  
  
  METHODS
  Anti-thymocyte globulin (ATG) followed by ciclosporin was administered to all patients for 15-18 months as the initial treatment. Haematological response was assessed 6 months after ATG administration and 6-monthly thereafter. Platelets were transfused if levels were <10 × 10(3)/l and for symptomatic bleeding. Transfusions of red blood cells were given for haemoglobin levels <70 g/l or symptomatic anaemia. Febrile neutropenia was managed with antibiotics, with the addition of antifungal agents after 3-4 days of unresponsive fever. Granulocyte colony-stimulating factor was administered at a dose of 5 µg/kg/day (maximum 300 µg/day) subcutaneously for infective episodes.
  
  
  METHODS
  
  
  
  METHODS
  overall survival. Secondary outcome: response to immunosuppressive therapy, failure-free survival, relapse and clonal evolutions. The response and relapse criteria were defined in accordance with the British Council for Standards in Haematology guidelines.
  
  
  RESULTS
  Overall response at 6 months after initiation of treatment was 85.8% (103/120). Overall survival at 76 months was 83.4%. Overall survival correlated with presence of response (complete response or partial response) at 6 months after ATG administration (HR=0.021, 95% CI 0.006 to 0.079, p<0.001). The occurrence of infectious complications adversely affected the overall survival (HR=5.71, 95% CI 1.22 to 26.77, p=0.027). Six patients relapsed. There were no deaths or adverse events 12 months after treatment among responders.
  
  
  CONCLUSIONS
  In our study, overall survival was 83.4% at a median follow-up of 76 months. The two variables that significantly affected overall survival were response to therapy at 6 months and occurrence of infectious complications.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, Army Hospital (Research and Referral Centre), New Delhi, India. nairvelu2000@yahoo.com
authors.forename: Velu
authors.initials: V
authors.lastname: Nair
authors.forename: Ajay
authors.initials: A
authors.lastname: Sharma
authors.forename: Satyaranjan
authors.initials: S
authors.lastname: Das
authors.forename: Vishal
authors.initials: V
authors.lastname: Sondhi
authors.forename: Sanjeevan
authors.initials: S
authors.lastname: Sharma
mesh_terms: D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D064147:Febrile Neutropenia / Q000188:drug therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016179:Granulocyte Colony-Stimulating Factor; D016572:Cyclosporine; C072115:nartograstim